Current Status of Predictive Biomarkers for Neoadjuvant Therapy in Esophageal Cancer

Overview

Journal World J Gastrointest Pathophysiol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Aug 19

PMID 25133032

Citations 11

Authors

Norihisa Uemura

Tadashi Kondo

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant therapy has been proven to be extremely valuable and is widely used for advanced esophageal cancer. However, a significant proportion of treated patients (60%-70%) does not respond well to neoadjuvant treatments and develop severe adverse effects. Therefore, predictive markers for individualization of multimodality treatments are urgently needed in esophageal cancer. Recently, molecular biomarkers that predict the response to neoadjuvant therapy have been explored in multimodal approaches in esophageal cancer and successful examples of biomarker identification have been reported. In this review, promising candidates for predictive molecular biomarkers developed by using multiple molecular approaches are reviewed. Moreover, treatment strategies based on the status of predicted biomarkers are discussed, while considering the international differences in the clinical background. However, in the absence of adequate treatment options related to the results of the biomarker test, the usefulness of these diagnostic tools is limited and new effective therapies for biomarker-identified nonresponders to cancer treatment should be concurrent with the progress of predictive technologies. Further improvement in the prognosis of esophageal cancer patients can be achieved through the introduction of novel therapeutic approaches in clinical practice.

Citing Articles

Risk Stratification by Tissue Expression Level in Curatively Resected Esophageal Squamous Cell Carcinoma.

Kishida T, Kanda M, Sato Y, Shimizu D, Inokawa Y, Hattori N Cancer Genomics Proteomics. 2023; 20(6):617-625.

PMID: 37889064 PMC: 10614066. DOI: 10.21873/cgp.20410.

Skeletal Muscle Loss During Neoadjuvant Chemotherapy Predicts the Incidence of Postoperative Infectious Complications in Esophageal Cancer Patients Undergoing Esophagectomy.

Higashizono K, Sato S, Nakatani E, Hawke P, Nagai E, Taki Y Cancer Diagn Progn. 2023; 3(1):67-74.

PMID: 36632592 PMC: 9801447. DOI: 10.21873/cdp.10181.

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma.

Matani H, Sahu D, Paskewicz M, Gorbunova A, Omstead A, Wegner R Biomark Res. 2022; 10(1):81.

PMID: 36376989 PMC: 9664643. DOI: 10.1186/s40364-022-00429-6.

, , : A Novel -Dependent Biomarker Triad of Glioblastoma at the Crossroads of Cytoskeleton Reorganization and Metabolism Alterations.

Kaluzinska Z, Kolat D, Bednarek A, Pluciennik E Cancers (Basel). 2021; 13(12).

PMID: 34204789 PMC: 8231639. DOI: 10.3390/cancers13122955.

Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.

Murakami T, Shoji Y, Nishi T, Chang S, Jachimowicz R, Hoshimoto S Mol Oncol. 2021; 15(4):1069-1087.

PMID: 33605536 PMC: 8024730. DOI: 10.1002/1878-0261.12929.

References

Lepage C, Rachet B, Jooste V, Faivre J, Coleman M . Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008; 103(11):2694-9. DOI: 10.1111/j.1572-0241.2008.02191.x. View

Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R . Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013; 17(9):1562-8. DOI: 10.1007/s11605-013-2259-5. View

Luthra R, Wu T, Luthra M, Izzo J, Lopez-Alvarez E, Zhang L . Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2005; 24(2):259-67. DOI: 10.1200/JCO.2005.03.3688. View

Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallbohmer D, Kocher M . Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2008; 20(2):231-8. DOI: 10.1093/annonc/mdn622. View

Hanash S, Pitteri S, Faca V . Mining the plasma proteome for cancer biomarkers. Nature. 2008; 452(7187):571-9. DOI: 10.1038/nature06916. View

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H . A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011; 19(1):68-74. DOI: 10.1245/s10434-011-2049-9. View

Zhang S, Huang Q, Yang H, Xie X, Luo K, Wen J . Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol. 2013; 20(7):2419-27. DOI: 10.1245/s10434-012-2859-4. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Hu Y, Correa A, Hoque A, Guan B, Ye F, Huang J . Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2010; 128(1):132-43. PMC: 2937084. DOI: 10.1002/ijc.25330. View

10.

Langer R, Feith M, Siewert J, Wester H, Hoefler H . Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008; 8:70. PMC: 2270853. DOI: 10.1186/1471-2407-8-70. View

11.

Nguyen N, Krafft S, Vinh-Hung V, Vos P, Almeida F, Jang S . Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol. 2011; 101(3):438-42. DOI: 10.1016/j.radonc.2011.07.015. View

12.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K . Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007; 17(7):497-504. DOI: 10.1097/FPC.0b013e328014341f. View

13.

Taylor C, Levenson R . Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006; 49(4):411-24. DOI: 10.1111/j.1365-2559.2006.02513.x. View

14.

Noble F, Hopkins J, Curtis N, Kelly J, Bailey I, Byrne J . The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol. 2013; 30(3):596. DOI: 10.1007/s12032-013-0596-6. View

15.

Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon J . Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011; 17(9):3029-38. DOI: 10.1158/1078-0432.CCR-10-2532. View

16.

Chen G, Gharib T, Huang C, Taylor J, Misek D, Kardia S . Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002; 1(4):304-13. DOI: 10.1074/mcp.m200008-mcp200. View

17.

Stiles B, Nasar A, Mirza F, Lee P, Paul S, Port J . Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg. 2012; 42(4):659-64. DOI: 10.1093/ejcts/ezs105. View

18.

Uehara H, Miyamoto M, Kato K, Cho Y, Kurokawa T, Murakami S . Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol. 2005; 92(2):109-15. DOI: 10.1002/jso.20332. View

19.

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

20.

Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S . Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 2009; 124(9):2106-15. DOI: 10.1002/ijc.24194. View